Show simple item record

dc.contributor.authorChristensen, Hen
dc.contributor.authorIrving, Ten
dc.contributor.authorKoch, Jen
dc.contributor.authorTrotter, Carolineen
dc.contributor.authorUltsch, Ben
dc.contributor.authorWeidemann, Fen
dc.contributor.authorWichmann, Oen
dc.contributor.authorHellenbrand, Wen
dc.date.accessioned2016-04-21T09:55:04Z
dc.date.available2016-04-21T09:55:04Z
dc.date.issued2016-04-22en
dc.identifier.issn0264-410X
dc.identifier.urihttps://www.repository.cam.ac.uk/handle/1810/255099
dc.description.abstractBexsero, a new vaccine against serogroup B meningococcal disease (MenB), was licensed in Europe in January 2013. In Germany, Bexsero is recommended for persons at increased risk of invasive meningococcal disease, but not for universal childhood vaccination. To support decision making we adapted the independently developed model for England to the German setting to predict the potential health impact and cost-effectiveness of universal vaccination with Bexsero® against MenB disease. We used both cohort and transmission dynamic mathematical models, the latter allowing for herd effects, to consider the impact of vaccination on individuals aged 0–99 years. Vaccination strategies included infant and adolescent vaccination, alone or in combination, and with one-off catch-up programmes. German specific data were used where possible from routine surveillance data and the literature. We assessed the impact of vaccination through cases averted and quality adjusted life years (QALY) gained and calculated costs per QALY gained. Assuming 65% vaccine uptake and 82% strain coverage, infant vaccination was estimated to prevent 15% (34) of MenB cases over the lifetime of one birth cohort. Including herd effects from vaccination increased the cases averted by infant vaccination to 22%, with an estimated 8461 infants requiring vaccination to prevent one case. In the short term the greatest health benefit is achieved through routine infant vaccination with large-scale catch-up, which could reduce cases by 24.9% after 5 years and 27.9% after 10 years. In the long term (20+ years) policies including routine adolescent vaccination are most favourable if herd effects are assumed. Under base case assumptions with a vaccine list price of €96.96 the incremental cost-effectiveness ratio (ICER) was >€500,000 per QALY for all considered strategies. Given the current very low incidence of MenB disease in Germany, universal vaccination with Bexsero® would prevent only a small absolute number of cases, at a high overall cost.
dc.description.sponsorshipThis work was supported by the Robert Koch Institute. HC’s work was supported by the National Institute for Health Research [RDA/03/07/014 and PDF-2012-05-245]. This work is produced by the authors under the terms of these research training fellowships issued by the NIHR. HC is a member of the NIHR Health Protection Research Unit in Evaluation of Interventions at University of Bristol. The views expressed in this publication are those of the authors and not necessarily those of the NHS, The National Institute for Health Research or the Department of Health. The NIHR had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
dc.languageEnglishen
dc.language.isoenen
dc.publisherElsevier
dc.rightsAttribution 4.0 International
dc.rightsAttribution 4.0 Internationalen
dc.rightsAttribution 4.0 Internationalen
dc.rightsAttribution 4.0 Internationalen
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/en
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/en
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/en
dc.subjectmeningococcal diseaseen
dc.subjectserogroup Ben
dc.subjectmodelen
dc.subjectcost-effectivenessen
dc.titleEpidemiological impact and cost-effectiveness of universal vaccination with Bexsero® to reduce meningococcal group B disease in Germanyen
dc.typeArticle
dc.description.versionThis is the final version of the article. It first appeared from Elsevier via https://doi.org/10.1016/j.vaccine.2016.04.004en
prism.endingPage3419
prism.publicationDate2016en
prism.publicationNameVaccineen
prism.startingPage3412
prism.volume34en
dc.rioxxterms.funderNIHR
dc.rioxxterms.projectidRDA/03/07/014
dc.rioxxterms.projectidPDF-2012-05-245
dcterms.dateAccepted2016-04-01en
rioxxterms.versionofrecord10.1016/j.vaccine.2016.04.004en
rioxxterms.licenseref.urihttp://creativecommons.org/licenses/by/4.0/en
rioxxterms.licenseref.startdate2016-04-22en
dc.contributor.orcidTrotter, Caroline [0000-0003-4000-2708]
dc.identifier.eissn1873-2518
rioxxterms.typeJournal Article/Reviewen
cam.orpheus.successThu Jan 30 12:54:06 GMT 2020 - The item has an open VoR version.*
rioxxterms.freetoread.startdate2100-01-01


Files in this item

Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record

Attribution 4.0 International
Except where otherwise noted, this item's licence is described as Attribution 4.0 International